786 related articles for article (PubMed ID: 19527758)
1. Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach.
Poli F; Cardillo M; Scalamogna M
Hum Immunol; 2009 Aug; 70(8):631-5. PubMed ID: 19527758
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant.
Claas FH; Doxiadis II
Hum Immunol; 2009 Aug; 70(8):636-9. PubMed ID: 19375467
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of complement-fixing antibodies in cardiac transplantation.
Rose ML; Smith JD
Hum Immunol; 2009 Aug; 70(8):605-9. PubMed ID: 19375471
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor.
Gupta A; Sinnott P
Hum Immunol; 2009 Aug; 70(8):618-22. PubMed ID: 19374932
[TBL] [Abstract][Full Text] [Related]
6. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums.
Gebel HM; Moussa O; Eckels DD; Bray RA
Hum Immunol; 2009 Aug; 70(8):610-7. PubMed ID: 19375473
[TBL] [Abstract][Full Text] [Related]
7. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.
Gibney EM; Cagle LR; Freed B; Warnell SE; Chan L; Wiseman AC
Nephrol Dial Transplant; 2006 Sep; 21(9):2625-9. PubMed ID: 16644776
[TBL] [Abstract][Full Text] [Related]
8. [Anti-HLA antibodies after bone graft and their impact on kidney transplant programs].
Mosconi G; Baraldi O; Fantinati C; Cappuccilli ML; Corsini S; Zanelli P; Bassi A; Buscaroli B; Feliciangeli G; Stefoni S
G Ital Nefrol; 2009; 26 Suppl 45():S58-63. PubMed ID: 19382096
[TBL] [Abstract][Full Text] [Related]
9. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
10. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools.
Eng HS; Bennett G; Bardy P; Coghlan P; Russ GR; Coates PT
Hum Immunol; 2009 Aug; 70(8):595-9. PubMed ID: 19527759
[TBL] [Abstract][Full Text] [Related]
12. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation.
Taylor CJ; Kosmoliaptsis V; Summers DM; Bradley JA
Hum Immunol; 2009 Aug; 70(8):563-8. PubMed ID: 19445992
[TBL] [Abstract][Full Text] [Related]
13. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
Aubert V; Venetz JP; Pantaleo G; Pascual M
Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
[TBL] [Abstract][Full Text] [Related]
14. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
Barocci S; Valente U; Nocera A
Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
[TBL] [Abstract][Full Text] [Related]
15. Pre- and posttransplant monitoring of alloantibodies by complement-dependent cytotoxicity and luminex methodologies in liver transplantation.
Monteiro F; Rodrigues H; Kalil J; Castro MC; Panajotopoulos N; Paredes M; Massarolo P; Mies S
Transplant Proc; 2012 Oct; 44(8):2411-2. PubMed ID: 23026608
[TBL] [Abstract][Full Text] [Related]
16. Cadaver kidney allocation in the north Italy transplant program on the eve of the new millennium.
Sirchia G; Poli F; Cardillo M; Scalamogna M; Rebulla P; Taioli E; Remuzzi G; Nocera A
Clin Transpl; 1998; ():133-45. PubMed ID: 10503092
[TBL] [Abstract][Full Text] [Related]
17. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility.
Castillo-Rama M; Castro MJ; Bernardo I; Meneu-Diaz JC; Elola-Olaso AM; Calleja-Antolin SM; Romo E; Morales P; Moreno E; Paz-Artal E
Liver Transpl; 2008 Apr; 14(4):554-62. PubMed ID: 18383092
[TBL] [Abstract][Full Text] [Related]
18. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
[TBL] [Abstract][Full Text] [Related]
19. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.
Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA
Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518
[TBL] [Abstract][Full Text] [Related]
20. Nebulous humors: defining alloantibodies in the 21st century.
Warner P
Hum Immunol; 2009 Aug; 70(8):623-6. PubMed ID: 19374934
[No Abstract] [Full Text] [Related]
[Next] [New Search]
